Renal Cell Carcinoma Drug Gains Approval


The FDA has approved axitinib (Inlyta, Pfizer) for the treatment of advanced renal cell carcinoma (RCC). The drug is given twice daily and indicated for patients who have not responded to other RCC cancer medications.

Source: FDA.

Submit a Comment

Your email address will not be published. Required fields are marked *

17 − 3 =